| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 May 2026 | 18 May 2026 |
| Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve (1) Migration of listing / trading of the equity shares from SME platform of BSE to main board of BSE and NSE, subject to shareholders approval, (2) making application of listing / trading of the Company on the main Board of NSE, subject to shareholders approval and (3) postal ballot notice for seeking approval of the members of the Company. The Board Meeting to be held on 22/05/2026 has been revised to 21/05/2026 The Board Meeting to be held on 22/05/2026 has been revised to 21/05/2026 Allotment of USD 10,000,000 8% Senior Unsecured Foreign Currency COnvertible Bonds Due 2029 of the Company. The Board of DIrectors at their meeting held today, 21/May/2026, inter alia, approved the following: 1) Migration of equity shares to main Board of BSE and NSE 2) Making Application for listing / tradin on main board of NSE 3) Postal Ballot Notice ofr seeking shareholders approval 4) Appointed Mr. Vishal Manseta, Company Secretary in Practice as the Scrutinizer. (As per BSE Announcement dated on: 21.05.2026) | ||
| Board Meeting | 15 May 2026 | 12 May 2026 |
| Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve the proposal for the issuance of Foreign Currency Convertible Bonds, subject to receipt of applicable regulatory and statutory approvals. Request you to take the same on record. In continuation to our earlier communication dated May 12, 2026, and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that pursuant to the approval of the members of the Company dated August 11, 2025, for the proposed issuance of foreign currency convertible bonds, and based on the In-principle approvals granted by BSE Limited dated September 25, 2025, the Board of Directors of the Company, at its meeting held on May 15, 2026, has, inter alia, considered and approved Issuance of upto U.S. $ 20,000,000 8.00% senior unsecured foreign currency convertible bonds due 2029, in one or more tranches, of Sudarshan Pharma Industries Limited (FCCBs); The details required to be disclosed as per Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 2023, is enclosed herewith as Annexure A. (As Per BSE Announcement Dated On : 15.05.2026). We refer to your email dated 16/05/2026 seeking additional details for the Outcome of Board Meeting made by the Company 15/05/2026 pertaining to approval of upto US $20,000,000 of 8% Senior Unsecured Foreign Currency Convertible Bonds due 2029. Query: Board meeting commencement and conclusion time is not given in pdf. Reply: We hereby submit the revised announcement as disclosed on 15/05/2026. (As per BSE announcement dated on :18.05.2026) | ||
| Board Meeting | 30 Apr 2026 | 27 Apr 2026 |
| Audited Results Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 ,inter alia, to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31/March/2026. Please find enclosed the Audited Financial Statements for the quarter and financial year ended 31-03-2026 (As Per BSE Annoncement Dated on:30.04.2026) | ||
| Board Meeting | 28 Jan 2026 | 22 Jan 2026 |
| Quarterly Results Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31/December/2025. (As Per BSE Announcement Dated on 22.01.2026) Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, please find attached the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31-12-2025 (As Per BSE Announcement Dated on:28.01.2026) | ||
| Board Meeting | 18 Oct 2025 | 15 Oct 2025 |
| Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/10/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-Sep-2025. Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, please find attached the Unaudited Financial Results for the quarter and half year ended 30-September-2025. (As Per BSE Announcement Dated on: 18/10/2025) | ||
| Board Meeting | 14 Aug 2025 | 11 Aug 2025 |
| Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve Sudarshan Pharma Industries Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2025. Please note that the Trading Window shall remain closed until the expiry of 48 hours after the declaration of the financial results for the quarter ended 30th June 2025. (As Per BSE Announcement Dated on: 14/08/2025) Please find enclosed herewith the newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2025, published in Financial Express and Mumbai Lakshdeep. (As per BSE Announcement Dated on 18.08.2025) | ||
| Board Meeting | 19 Jun 2025 | 16 Jun 2025 |
| Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/06/2025 inter alia to consider and approve the proposal for raising further funds by way of issuance of equity shares or any other equity linked instruments or securities including convertible instruments warrants etc subject to applicable approvals. The Board of Directors at their meeting held today, 19th June 2025 has approved the proposal to raising of funds by way of issuance of equity shares and / or eligible securities through permissible modes in one or more tranches, for an amount not exceeding Rs.1500 Crores or equivalent amount in foreign currency, subject to approval of the regulatory / statutory authorities. This is to inform you that the Board of Directors of the Company at their meeting held today i.e. 19/06/2025 have approved to incorporate a wholly-owned subsidiary Company in Canada. (As per BSE Announcement Dated on 19/06/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
